ERAS · Erasca, Inc.

Erasca, Inc. faces significant intellectual property challenges regarding its pan-RAS molecular glue candidate ERAS-0015. On April 24, 2026, the Company received a letter from legal counsel for Revolution Medicines, Inc. alleging patent infringement, trade secret misappropriation, and deceptive public comparisons. The patent infringement claim centers on U.S. Patent No. 12,409,225, with RevMed asserting that ERAS-0015 is substantially equivalent to claimed compositions under the doctrine of equivalents. The trade secret allegation involves claims that a third party misappropriated RevMed secrets connected to an ERAS-0015 patent, extending liability to Erasca as a licensee. RevMed has demanded an immediate cessation of all commercialization activities for ERAS-0015 in the United States outside the Hatch-Waxman safe harbor. Erasca has rejected these claims, stating the assertions are without merit and committing to a vigorous defense. Concurrently, the Company is proceeding with the disclosure of preliminary Phase 1 dose escalation data for ERAS-0015, indicating continued clinical progress despite the legal dispute. The outcome of this dispute poses material risk to the ERAS-0015 program and potentially the Company’s valuation.